JP2013526559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526559A5 JP2013526559A5 JP2013510600A JP2013510600A JP2013526559A5 JP 2013526559 A5 JP2013526559 A5 JP 2013526559A5 JP 2013510600 A JP2013510600 A JP 2013510600A JP 2013510600 A JP2013510600 A JP 2013510600A JP 2013526559 A5 JP2013526559 A5 JP 2013526559A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- independently
- hydrogen
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 50
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000002947 alkylene group Chemical group 0.000 claims 20
- 125000004122 cyclic group Chemical group 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- -1 —NH 2 Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 0 CC(C)C(C1=O)=CC=**1I(C)C Chemical compound CC(C)C(C1=O)=CC=**1I(C)C 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10163019.2 | 2010-05-17 | ||
| EP10163019 | 2010-05-17 | ||
| PCT/EP2011/057985 WO2011144622A1 (en) | 2010-05-17 | 2011-05-17 | 1h - imidazo [4, 5 - c] quinolines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013526559A JP2013526559A (ja) | 2013-06-24 |
| JP2013526559A5 true JP2013526559A5 (enExample) | 2014-07-10 |
| JP5863058B2 JP5863058B2 (ja) | 2016-02-16 |
Family
ID=42989490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510600A Active JP5863058B2 (ja) | 2010-05-17 | 2011-05-17 | １Ｈ−イミダゾ［４，５−ｃ］キノリン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8895581B2 (enExample) |
| EP (1) | EP2571877B1 (enExample) |
| JP (1) | JP5863058B2 (enExample) |
| WO (1) | WO2011144622A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2571877B1 (en) | 2010-05-17 | 2018-08-15 | Boehringer Ingelheim International GmbH | 1h-imidazo[4,5-c]quinolines |
| CA2878054C (en) | 2012-06-29 | 2018-09-11 | Pfizer Inc. | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| US9227969B2 (en) * | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| PL3068401T3 (pl) * | 2013-11-15 | 2019-08-30 | Oncoceutics, Inc. | 7-Benzylo-4-(2-metylobenzylo)-2,4,6,7,8,9-heksahydroimidazo[1,2-a]pirydo[3,4-e]pirymidyn- 5(1H)-on, jego sole i sposoby zastosowania |
| JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン |
| CN107427516B8 (zh) | 2015-01-30 | 2021-04-09 | 昂克希尔迪克斯有限公司 | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 |
| WO2017046675A1 (en) * | 2015-09-14 | 2017-03-23 | Pfizer Inc. | Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors |
| EP3592741B1 (en) * | 2017-03-10 | 2023-02-15 | Pfizer Inc. | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
| WO2020037092A1 (en) * | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Imidazo[4,5-c]quinoline derived nlrp3-modulators |
| US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
| WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| WO2023283213A1 (en) | 2021-07-07 | 2023-01-12 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| US12030883B2 (en) | 2021-09-21 | 2024-07-09 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of KRAS |
| JP2024537824A (ja) | 2021-10-01 | 2024-10-16 | インサイト・コーポレイション | ピラゾロキノリンｋｒａｓ阻害剤 |
| MX2024004444A (es) | 2021-10-14 | 2024-05-08 | Incyte Corp | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| BRPI0416801A (pt) | 2003-11-21 | 2007-01-09 | Novartis Ag | derivados de 1h-imidazoquinolina como inibidores de proteìna sinase |
| AR046845A1 (es) | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| MX2008007864A (es) | 2005-12-16 | 2009-03-04 | Coley Pharm Group Inc | Imidazoquinolinas, imidazonaftiridinas, e imidazopiridinas sustituidas, composiciones y metodos. |
| JP5642963B2 (ja) * | 2006-06-30 | 2014-12-17 | スネシス ファーマシューティカルズ，インコーポレイティド | ピリジノニルｐｄｋ１阻害剤 |
| UY31984A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
| UY31982A (es) * | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| US8575203B2 (en) * | 2010-04-21 | 2013-11-05 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| EP2571877B1 (en) | 2010-05-17 | 2018-08-15 | Boehringer Ingelheim International GmbH | 1h-imidazo[4,5-c]quinolines |
-
2011
- 2011-05-17 EP EP11720100.4A patent/EP2571877B1/en active Active
- 2011-05-17 WO PCT/EP2011/057985 patent/WO2011144622A1/en not_active Ceased
- 2011-05-17 US US13/697,034 patent/US8895581B2/en active Active
- 2011-05-17 JP JP2013510600A patent/JP5863058B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013526559A5 (enExample) | ||
| JP2013525333A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| JP2017527532A5 (enExample) | ||
| JP2013523614A5 (enExample) | ||
| JP2015500843A5 (enExample) | ||
| JP2014500296A5 (enExample) | ||
| JP2014504622A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2017510610A5 (enExample) | ||
| JP2013502430A5 (enExample) | ||
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| JP2014507421A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| RU2011143741A (ru) | Производное индолизина и его применение в медицинских целях | |
| JP2014511892A5 (enExample) | ||
| JP2011529468A5 (enExample) | ||
| JP2013500314A5 (enExample) | ||
| RU2015106730A (ru) | Фармацевтическая или косметическая композиция для лечения алопеции | |
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2015536947A5 (enExample) | ||
| JP2019500387A5 (enExample) |